Table 5.
Effect of i.v. 212Pb-Radioimmunotherapy in Combination with Chemotherapeutics on the Weights of Athymic Mice Bearing LS-174T i.p. Tumor Xenografts
| Days post 212Pb-RIT | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| F(ab′)2 | Chemotherapeutic | −1 | 5 | 8 | 12 | 15 | 19 | 26 | 29 | 33 |
| None | None | 22.3 ± 1.0 | 22.6 ± 1.2 | 23.9 ± 1.2 | ||||||
| None | GEM | 22.6 ± 1.3 | 21.7 ± 1.7 | 22.4 ± 1.8 | 23.1 ± 2.1 | 21.5 | ||||
| None | Paclitaxel | 22.9 ± 2.0 | 21.9 ± 2.4 | 23.0 ± 2.5 | 23.1 ± 2.2 | 23.0 ± 2.2 | 25.1 ± 0.2 | 24.0 | 24.5 | 24.2 |
| Panitumumab | None | 25.1 ± 2.0 | 21.9 ± 1.9 | 24.0 ± 1.9 | 21.8 ± 2.3 | 21.8 ± 2.3 | 22.8 ± 1.8 | 22.0 ± 2.0 | 21.7 ± 1.9 | 21.1 ± 1.7 |
| Panitumumab | GEM | 24.3 ± 1.2 | 20.0 ± 1.9 | 21.6 ± 2.2 | 21.3 ± 2.0 | 21.7 ± 2.0 | 22.7 ± 2.1 | 22.7 ± 1.7 | 22.5 ± 1.8 | 22.5 ± 2.2 |
| Panitumumab | Paclitaxel | 23.7 ± 2.4 | 18.8 ± 2.5 | 20.5 ± 2.8 | 21.1 ± 2.0 | 22.8 ± 2.7 | 24.1 ± 2.3 | 23.3 ± 1.7 | 23.5 ± 1.8 | 23.4 ± 2.5 |
| HuM195 | None | 21.9 ± 1.7 | 19.3 ± 1.9 | 19.2 ± 2.9 | 23.7 ± 2.2 | |||||
| HuM195 | GEM | 22.7 ± 0.9 | 20.3 ± 1.5 | 19.2 ± 1.5 | 19.1 ± 1.4 | |||||
| HuM195 | Paclitaxel | 23.0 ± 2.7 | 21.6 ± 3.0 | 20.3 ± 2.5 | 21.7 ± 3.2 | |||||
Paclitaxel (0.6 mg) and gemcitabine (1 mg) were administered i.p. to mice bearing LS-174T i.p. tumor 24 h before RIT. The 212Pb-panitumumab F(ab′)2 (20 μCi) was administered by i.v. injection. Animal weights were then monitored one to two times per week for 5 weeks as an indicator of toxicity. Additional groups included those that received no treatment, GEM or paclitaxel only, 212Pb-panitumumab F(ab′)2, 212Pb-HuM195 F(ab′)2, and 212Pb-HuM195 F(ab′)2 in combination with GEM or paclitaxel.